Urge your Representative and Senators to Support Improved Medicaid Coverage of Clinical Trials!
The CLINICAL TREATMENT Act, H.R. 913, was introduced by Representatives Ben Ray Lujan (D-NM-03) and Gus Bilirakis (R-FL-12) to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition or disability.
Clinical trials are a critical weapon in the fight against ME/CFS.
Medicaid insures nearly one-fifth of the U.S. population and is the only major payer that is
required by federal law to provide coverage of the routine care costs for participating in a clinical trial. Improved access and coverage of clinical trial participation benefits ME/CFS patients and
helps reduce the cost of clinical trials
. This is vital for under-funded diseases, like ME/CFS, which struggles to secure funds for clinical trial research.
Medicaid serves a large portion of under-represented minorities, ethnicites, and disabilities that are not well represented in traditional clinical trial enrollment. The Clinical Treatment Act (H.R. 913) is one step towards improving the representation of ME/CFS patients in clinical trials and reducing the cost of ME/CFS clinical trials in the future.
click here for blank form
District of Columbia
Subscribe to Email Alerts?
Add a Personal Message
Hello - I am a constituent who cares about myalgic encephalomyelitis, also known as chronic fatigue syndrome or ME/CFS. ME/CFS affects an estimated 2.5 million Americans and costs our economy between $17 billion and $24 billion each year. I am writing to ask you to cosponsor the CLINICAL TREATMENT Act, H.R. 913, which would provide Medicaid coverage of the routine care costs of clinical trials participation. Clinical trials are a critical weapon in the fight against ME/CFS. Without robust patient participation in trials, research progress slows. Routine care costs include the non-experimental costs of treating a patient who is participating in a clinical trial, such as physician visits and laboratory studies. This coverage is already assured for Medicare beneficiaries as well as individuals with private insurance coverage, leaving Medicaid as the last major payer not required to do so. Please cosponsor and support the CLINICAL TREATMENT Act, H.R. 913, helping ensure participation in clinical research, reducing the cost of clinical trials, and continuing development of improved treatments for misunderstood and underfunded diseases, like ME/CFS. Thank you.
Your Elected Officials